Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Pleiotropic pathway modifier

DRUG CLASS:

Pleiotropic pathway modifier

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab + CC-122 Sensitive: C3 – Early Trials rituximab + CC-122 Sensitive : C3	rituximab + CC-122 Sensitive: C3 – Early Trials rituximab + CC-122 Sensitive : C3
IKZF1 deletion + IKZF3 deletion	Diffuse Large B Cell Lymphoma	IKZF1 deletion + IKZF3 deletion	Diffuse Large B Cell Lymphoma	CC-122 Sensitive: C4 – Case Studies CC-122 Sensitive : C4	CC-122 Sensitive: C4 – Case Studies CC-122 Sensitive : C4
IKZF1 G151A overexpression	Diffuse Large B Cell Lymphoma	IKZF1 G151A overexpression	Diffuse Large B Cell Lymphoma	CC-122 Resistant: C4 – Case Studies CC-122 Resistant : C4	CC-122 Resistant: C4 – Case Studies CC-122 Resistant : C4
IKZF3 G152A overexpression	Diffuse Large B Cell Lymphoma	IKZF3 G152A overexpression	Diffuse Large B Cell Lymphoma	CC-122 Resistant: C4 – Case Studies CC-122 Resistant : C4	CC-122 Resistant: C4 – Case Studies CC-122 Resistant : C4